These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1050 related articles for article (PubMed ID: 34894519)

  • 1. Therapeutic potential of CAR T cell in malignancies: A scoping review.
    Mehrabadi AZ; Ranjbar R; Farzanehpour M; Shahriary A; Dorostkar R; Hamidinejad MA; Ghaleh HEG
    Biomed Pharmacother; 2022 Feb; 146():112512. PubMed ID: 34894519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-tagging by oncolytic viruses: A novel strategy for CAR-T therapy against solid tumors.
    Tang XY; Ding YS; Zhou T; Wang X; Yang Y
    Cancer Lett; 2021 Apr; 503():69-74. PubMed ID: 33476650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Review of CAR-T Combination Therapies for Treatment of Gynecological Cancers.
    Olifirenko V; Barlev NA
    Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic viruses improve cancer immunotherapy by reprogramming solid tumor microenvironment.
    Zhang L; Pakmehr SA; Shahhosseini R; Hariri M; Fakhrioliaei A; Karkon Shayan F; Xiang W; Karkon Shayan S
    Med Oncol; 2023 Dec; 41(1):8. PubMed ID: 38062315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors.
    Porter CE; Rosewell Shaw A; Jung Y; Yip T; Castro PD; Sandulache VC; Sikora A; Gottschalk S; Ittman MM; Brenner MK; Suzuki M
    Mol Ther; 2020 May; 28(5):1251-1262. PubMed ID: 32145203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CAR-T cell therapy: current limitations and potential strategies.
    Sterner RC; Sterner RM
    Blood Cancer J; 2021 Apr; 11(4):69. PubMed ID: 33824268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current progress in chimeric antigen receptor T cell therapy for glioblastoma multiforme.
    Marei HE; Althani A; Afifi N; Hasan A; Caceci T; Pozzoli G; Cenciarelli C
    Cancer Med; 2021 Aug; 10(15):5019-5030. PubMed ID: 34145792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges of chimeric antigen receptor-T/natural killer cell therapy in the treatment of solid tumors: focus on colorectal cancer and evaluation of combination therapies.
    Wang H; Pan W
    Mol Cell Biochem; 2023 May; 478(5):967-980. PubMed ID: 36190614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CAR-T Cells and Oncolytic Viruses: Joining Forces to Overcome the Solid Tumor Challenge.
    Guedan S; Alemany R
    Front Immunol; 2018; 9():2460. PubMed ID: 30405639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineering for Success: Approaches to Improve Chimeric Antigen Receptor T Cell Therapy for Solid Tumors.
    Mata M; Gottschalk S
    Drugs; 2019 Mar; 79(4):401-415. PubMed ID: 30796733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Befriending the Hostile Tumor Microenvironment in CAR T-Cell Therapy.
    Lindo L; Wilkinson LH; Hay KA
    Front Immunol; 2020; 11():618387. PubMed ID: 33643299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The synergistic immunotherapeutic impact of engineered CAR-T cells with PD-1 blockade in lymphomas and solid tumors: a systematic review.
    Satapathy BP; Sheoran P; Yadav R; Chettri D; Sonowal D; Dash CP; Dhaka P; Uttam V; Yadav R; Jain M; Jain A
    Front Immunol; 2024; 15():1389971. PubMed ID: 38799440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive clinical evaluation of CAR-T cell immunotherapy for solid tumors: a path moving forward or a dead end?
    Drougkas K; Karampinos K; Karavolias I; Koumprentziotis IA; Ploumaki I; Triantafyllou E; Trontzas I; Kotteas E
    J Cancer Res Clin Oncol; 2023 Jun; 149(6):2709-2734. PubMed ID: 36564524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel technologies for improving the safety and efficacy of CAR-T cell therapy.
    Ohta K; Sakoda Y; Tamada K
    Int J Hematol; 2023 May; 117(5):647-651. PubMed ID: 36309630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
    Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
    Front Immunol; 2018; 9():1717. PubMed ID: 30108584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical CAR-T Cell and Oncolytic Virotherapy for Cancer Treatment.
    Watanabe N; McKenna MK; Rosewell Shaw A; Suzuki M
    Mol Ther; 2021 Feb; 29(2):505-520. PubMed ID: 33130314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment.
    Shi T; Song X; Wang Y; Liu F; Wei J
    Front Immunol; 2020; 11():683. PubMed ID: 32411132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors.
    Kosti P; Maher J; Arnold JN
    Front Immunol; 2018; 9():1104. PubMed ID: 29872437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CAR-T Therapies in Solid Tumors: Opportunities and Challenges.
    Guzman G; Reed MR; Bielamowicz K; Koss B; Rodriguez A
    Curr Oncol Rep; 2023 May; 25(5):479-489. PubMed ID: 36853475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. INSPIRED Symposium Part 5: Expanding the Use of CAR T Cells in Children and Young Adults.
    Talleur AC; Fabrizio VA; Aplenc R; Grupp SA; Mackall C; Majzner R; Nguyen R; Rouce R; Moskop A; McNerney KO
    Transplant Cell Ther; 2024 Jun; 30(6):565-579. PubMed ID: 38588880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.